A groundbreaking ocular implant developed by scientists at Stanford University is making a significant impact, allowing some blind adults to read, recognize faces, and even express their creativity through art once more.
This small prosthetic device, known as the PRIMA Retinal Implant System, is even smaller than a standard contact lens and has already aided numerous patients in regaining valuable vision during clinical trials in Europe.
The device primarily aims to address age-related macular degeneration, which affects about one million people in the U.S. and is a common contributor to blindness in older adults.
The implant was created by Daniel Palankar, a Stanford ophthalmologist and electrical engineer. It features a 2-by-2-millimeter disk embedded with 370 light-sensitive pixels, surgically positioned just behind the retina.
After implantation, patients need to don specialized augmented reality glasses equipped with a camera. These glasses capture images and beam them as near-infrared light to the implant.
The solar-powered pixels then convert this incoming light into electrical signals that stimulate surviving retinal cells, relaying information to the brain.
Recent clinical trials revealed that out of 32 patients, 26 showed marked improvements in visual acuity after one year of training. The findings, published in the New England Medical Journal, reported an average improvement of five lines on a standard eye chart. Some participants, who could only glimpse the top line initially, can now read large print and complete everyday tasks, with one individual experiencing a remarkable improvement of 12 lines.
The Alameda-based Science Corporation, which is working to commercialize this technology, is aiming for approval from European authorities this summer. While approval from the U.S. Food and Drug Administration will take longer, the company is seeking a humanitarian device exemption to expedite the process.
Palankar, who had previously invented a laser for cataract surgeries, notes that the device’s main advancement lies in using light rather than wires for power and control.
“Historically, attempts to restore vision resulted only in perceptions of light and shape,” he states. “I believe our success lies in how effectively we encoded visual information for the brain to process.”
Efforts are already underway to adapt the device for other types of vision loss, such as Stargardt disease, with researchers looking to enhance resolution significantly in the next iteration of the PRIMA system.
This technology doesn’t just restore sight; it brings back autonomy and joy for its users.
Jason Menzo, CEO of the Foundation to Fight Blindness, highlighted that innovations in this field, including gene therapy and stem cell treatments, are pushing the boundaries of vision restoration. “This field has never been more advanced than it is today,” he remarked.
Menzo also expressed that the mere existence of such technologies, regardless of whether an individual ultimately receives a device, can uplift spirits and foster hope among patients.
